However, the data from the validation cohort of NB patients, in vitro screening, and in silico data mining across cell lines, as well as experimental NB studies by others, are in agreement and conceptually affirm the acquired RD3 loss with IMCT in surviving cells. The gene discussed is RD3; the disease is neuroblastoma.